13 research outputs found
ΠΠ½ΡΠΈΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π² ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ
In the article the authors revise a number of methods used in clinic for the description of hypercoagulation syndrome and consider that persistent trombinemia signs and signs of platelet hyperaggregation with the increased consumption of them are the most reliable markers of hypercoagulation and prethrombosis state. Methodology of oncothrombosis prophylaxis and therapy is discussed. Authors demonstrate that heparin therapy decreases the risk of development of spontaneous and postsurgery thrombosis as well as of DIC-syndrome in cancer patients. Authors define the ways of further optimization of thrombotic complications prophylaxis and therapy using thrombine inhibitors and the study of their effects on oncogenesis.Π ΡΡΠ°ΡΡΠ΅ Π°Π²ΡΠΎΡΡ ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π°ΡΡ ΠΏΠ΅ΡΠ΅ΡΠΌΠΎΡΡΡ ΡΡΠ΄ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ², ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
Π² ΠΊΠ»ΠΈΠ½ΠΈΠΊΠ΅ Π΄Π»Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ Π³ΠΈΠΏΠ΅ΡΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ°, ΠΈ ΡΡΠΈΡΠ°ΡΡ Π±ΠΎΠ»Π΅Π΅ Π½Π°Π΄Π΅ΠΆΠ½ΡΠΌΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠ°ΠΌΠΈ Π³ΠΈΠΏΠ΅ΡΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΈ ΠΏΡΠ΅Π΄ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΈ ΠΏΠ΅ΡΡΠΈΡΡΠΈΡΡΡΡΠ΅ΠΉ ΡΡΠΎΠΌΠ±ΠΈΠ½Π΅ΠΌΠΈΠΈ ΠΈ Π³ΠΈΠΏΠ΅ΡΠ°Π³ΡΠ΅Π³Π°ΡΠΈΠΈ ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΠΈΡ
ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΠ΅ΠΌ. ΠΠ±ΡΡΠΆΠ΄Π°Π΅ΡΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΠ½ΠΊΠΎΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ². ΠΠ²ΡΠΎΡΡ ΠΏΠΎΠΊΠ°Π·ΡΠ²Π°ΡΡ, ΡΡΠΎ Π³Π΅ΠΏΠ°ΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠ½ΠΈΠΆΠ°Π΅Ρ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΏΠΎΠ½ΡΠ°Π½Π½ΡΡ
ΠΈ ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΡΡΠΎΠΌΠ±ΠΎΠ·ΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΠΠΠ‘-ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠ²ΡΠΎΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡ ΠΏΡΡΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΉ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΡΠΎΠΌΠ±ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠΎΠ² ΡΡΠΎΠΌΠ±ΠΎΡΠΈΡΠΎΠ² ΠΈ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈΡ
Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° ΠΎΠ½ΠΊΠΎΠ³Π΅Π½Π΅Π·
Π‘ΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠΈ ΡΡΡΠ΅ΠΊΡΠΎΠ² Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠΎΠ² Π²ΠΎΠ»ΡΠ°Π½ΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠΈΠΏΠ° Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠ΄ΠΎΠ² Π³Π°Π΄ΡΠΊΠΈ Π Π°ΡΡΠ΅Π»Π»Π° ΠΈ Π³ΡΡΠ·Ρ ΡΡΠ΅Π΄Π½Π΅Π°Π·ΠΈΠ°ΡΡΠΊΠΎΠΉ
For identification of lupous anticoagulant (LA) effects tests with phospholipin-dependent coagulase of snake venoms are used. Abroad they use the diluted Russell viper venom for this purpose.Investigations carried out by the authors on 31 patients (10 men and 21 women) aged 25-51 with antiphospholipin syndrome registered by clinical and laboratory criterions, have shown that the coagulation test with diluted Central Asian gyurza (Vipera lebetina turanica) venom could be used for the same purpose, its coagulase by the action mechanism is close to the coagulase of Russell viper venom (Vipers Russelli).ΠΠ»Ρ ΠΈΠ΄Π΅Π½ΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΡΡΡΠ΅ΠΊΡΠΎΠ² Π²ΠΎΠ»ΡΠ°Π½ΠΎΡΠ½ΡΡ
Π°Π½ΡΠΈΠΊΠΎΠ°Π³ΡΠ»ΡΠ½ΡΠΎΠ² (ΠΠ) ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ ΡΠ΅ΡΡΡ Ρ ΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌΠΈ ΠΊΠΎΠ°Π³ΡΠ»Π°Π·Π°ΠΌΠΈ Π·ΠΌΠ΅ΠΈΠ½ΡΡ
ΡΠ΄ΠΎΠ². ΠΠ° ΡΡΠ±Π΅ΠΆΠΎΠΌ Ρ ΡΡΠΎΠΉ ΡΠ΅Π»ΡΡ ΠΏΡΠΈΠΌΠ΅Π½ΡΡΡ ΡΠ°Π·Π²Π΅Π΄Π΅Π½Π½ΡΠΉ ΡΠ΄ Π³Π°Π΄ΡΠΊΠΈ Π Π°ΡΡΠ΅Π»Π»Π°.ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΡΠ΅ Π°Π²ΡΠΎΡΠ°ΠΌΠΈ ΡΡΠ°ΡΡΠΈ Π½Π° 31 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ΅ (10 ΠΌΡΠΆΡΠΈΠ½ ΠΈ 21 ΠΆΠ΅Π½ΡΠΈΠ½Π°) Π² Π²ΠΎΠ·ΡΠ°ΡΡΠ΅ ΠΎΡ 25 Π΄ΠΎ 51 Π³ΠΎΠ΄Π° Ρ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΠΏΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΡΠΌ ΠΊΡΠΈΡΠ΅ΡΠΈΡΠΌ Π°Π½ΡΠΈΡΠΎΡΡΠΎΠ»ΠΈΠΏΠΈΠ΄Π½ΡΠΌ ΡΠΈΠ½Π΄ΡΠΎΠΌΠΎΠΌ, ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ Ρ ΡΡΠΎΠΉ ΠΆΠ΅ ΡΠ΅Π»ΡΡ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ ΠΊΠΎΠ°Π³ΡΠ»ΡΡΠΈΠΎΠ½Π½ΡΠΉ ΡΠ΅ΡΡ Ρ ΡΠ°Π·Π²Π΅Π΄Π΅Π½Π½ΡΠΌ ΡΠ΄ΠΎΠΌ Π³ΡΡΠ·Ρ ΡΡΠ΅Π΄Π½Π΅Π°Π·ΠΈΠ°ΡΡΠΊΠΎΠΉ (Vipera lebetina turanica), ΠΊΠΎΠ°Π³ΡΠ»Π°Π·Π° ΠΊΠΎΡΠΎΡΠΎΠ³ΠΎ ΠΏΠΎ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π±Π»ΠΈΠ·ΠΊΠ° ΠΊ ΠΊΠΎΠ°Π³ΡΠ»Π°Π·Π΅ ΡΠ΄Π° Π³Π°Π΄ΡΠΊΠΈ Π Π°ΡΡΠ΅Π»Π»Π° (Vipera Russelli)
Safety of low-molecular-weight heparin in pregnancy: a systematic review
Unfractionated heparin (UFH) remains the anticoagulant of choice during pregnancy. Low-molecular-weight heparins (LMWH) are an attractive alternative to UFH due to their logistic advantages and their association with a lower incidence of osteoporosis and HIT. We reviewed all published clinical reports concerning the use of LMWH during pregnancy. In addition, participants of an international interest group contributed a cohort of pregnant women treated with LMWH. Pregnancies were divided into two groups; those with and those without maternal comorbid conditions. The number of adverse fetal outcomes and the occurrence of maternal complications were evaluated in the two groups. In the group of women with comorbid conditions (n = 290), 13.4% of the pregnancies were associated with an adverse fetal outcome. In contrast, in the group of women without comorbid conditions (n = 196), 3.1% were associated with an adverse outcome, which is comparable to that seen in the normal population. We conclude that LMWH appear to be a safe alternative to unfractionated heparin as an anticoagulant during pregnanc